large b-cell lymphoma

Take a break and read all about it

Announcements

FDA grants accelerated approval to Tafasitamab-cxix for diffuse large B-cell lymphoma

As of January 2021, the Food and Drug Administration (FDA) has announced the approval of a new medication for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma, who are not eligible for autologous stem cell transplant. The new drug, called Monjuvi (tafasitimab) is a targeted therapy that will be used in combination with lenalidomide (Revlimid). Other combinations are currently under investigation.

Do You Want To Boost Your Business?

drop us a line and keep in touch

GVCC giveaway

Register and attend GVCC to win!

Happening virtually on November 2nd-5th, 2022, our fourth annual conference has sessions geared toward cancer patients, survivors, caregivers, advocates, cancer care professionals, and new this year, those interested in early detection and prevention.